Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study hopes to predict hodgkin lymphoma outcomes better

NCT ID NCT06822855

Knowledge-focused Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study is looking for better ways to predict how Hodgkin lymphoma will progress. Researchers will analyze genetic material from tumor samples and blood tests, along with PET scan images, from 755 patients. The goal is to identify markers that could help doctors personalize treatment, potentially increasing cure rates while reducing long-term side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to more personalized treatment plans for Hodgkin lymphoma, potentially improving cure rates and reducing side effects.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may not immediately change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 755 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will involve three patient cohorts, with participants recruited from multiple centers across Italy during routine follow-up visits. Cohort A will include 70 patients with classical Hodgkin lymphoma (cHL) who have a histological confirmation of relapse or progression. These patients will be enrolled at the time of disease relapse/progression, and plasma samples for ctDNA analysis will be collected concurrently. Cohort B will consist of 200 cHL patients who have completed active treatment and entered the follow-up phase. Plasma samples will be collected from these patients at the time of enrollment (P0) and again at a six-month follow-up (P6FU). This cohort will be followed for a minimum of two years from the time of enrollment. Cohort C is a retrospective cohort that will be divided into two subgroups: Training cohort: 235 consecutive cHL patients collected from the archives of the Hematology Unit of AUSL-IRCCS between 2004 and 2019. This cohort is representative of the ge

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 anni * Written informed consent signed Cohort A * Age \>18 years * Histologically confirmed diagnosis of relapsed/refractory classical Hodgkin lymphoma identified during induction or follow-up * Available formalin-fixed, paraffin-embedded (FFPE) biopsy at diagnosis and at the time of progression/relapse * Available plasma sample at progression (before the beginning of salvage therapy) * Available FDG-PET evaluation at study enrollment * Available clinical, laboratory, and radiologic data at diagnosis and relapse Cohort B * Diagnosis of classical Hodgkin lymphoma * Completion of first-line standard systemic treatment (chemotherapy-based or chemoradiotherapy combined modality) * Available plasma sample at the end of treatment (at least 30 days from the last chemotherapy) * Available FFPE biopsy at diagnosis * No further treatment planned * Available clinical, laboratory, and radiologic data at diagnosis and response evaluation * Patient's willingness to undergo 6 months follow-up plasma sample collection and to attend regular follow-up Cohort C * Histologically confirmed diagnosis of classical Hodgkin lymphoma * Standard treatment as per available guidelines (e.g., ESMO guidelines) * Available treatment data, response, and follow-up data * Available FFPE biopsy at diagnosis * Available FDG-PET evaluation at study enrollment Exclusion Criteria: * Patients with nodular lymphocyte predominant Hodgkin lymphoma are not eligible; all other subtypes including nodular sclerosis, lymphocyte-depleted, lymphocyte-rich, and mixed cellularity Hodgkin lymphoma may be enrolled. * Active HIV, HBV, HCV viral infection * Concomitant neoplasm not treated with a curative aim

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Classical Hodgkin lymphoma Classical Hodgkin lymphoma recurrent Classical Hodgkin lymphoma refractory

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.S.G. Moscati

    RECRUITING

    Avellino, Italy

  • AOU Città della Salute e della Scienza

    RECRUITING

    Torino, Italy

  • AOU Città della salute e della Scienza, "Le Molinette"

    RECRUITING

    Torino, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    RECRUITING

    Milan, MI, 20162, Italy

  • AUSL Piacenza

    RECRUITING

    Piacenza, Italy

  • Azienda Ospedaliera "Ospedali Riuniti Villa Sofia-Cervello"

    RECRUITING

    Palermo, Italy

  • Azienda Ospedaliera Santa Maria - Terni

    RECRUITING

    Terni, 05100, Italy

  • Azienda Ospedaliera di Perugia

    RECRUITING

    Perugia, Italy

  • Azienda USL IRCCS di Reggio Emilia

    RECRUITING

    Reggio Emilia, RE, 42123, Italy

  • Istituto Oncologico Veneto

    RECRUITING

    Padova, Italy

  • Ospedale S. Maria della Misericordia, Azienda Ospedaliera di Perugia

    RECRUITING

    Perugia, Italy

  • Spedali Civili Brescia

    RECRUITING

    Brescia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.